Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.

Author(s): Price DK,  Chau CH,  Till C,  Goodman PJ,  Baum CE,  Ockers SB,  English BC,  Minasian L,  Parnes HL,  Hsing AW,  Reichardt JK,  Hoque A,  Tangen CM,  Kristal AR,  Thompson IM,  Figg WD

Journal: J Urol

Date: 2010 Dec

Major Program(s) or Research Group(s): PUCRG, CCOP, COPTRG

PubMed ID: 20952028

PMC ID: PMC3930175

Abstract: PURPOSE: We investigated the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer. MATERIALS AND METHODS: This is a nested case-control study of 1,159 cases and 1,353 controls from the Prostate Cancer Prevention Trial, a randomized, placebo controlled trial testing whether the 5α-reductase inhibitor finasteride could decrease the 7-year prevalence of prostate cancer. During the course of the trial men underwent annual digital rectal examination and prostate specific antigen measurement. Prostate biopsy was recommended in all men with abnormal digital rectal examination or finasteride adjusted prostate specific antigen greater than 4.0 ng/ml. Cases were drawn from men with biopsy determined prostate cancer identified by for cause or end of study biopsy. Controls were selected from men who completed the end of study biopsy. RESULTS: Mean CAG repeat length did not differ between cases and controls. The frequency distribution of cases and controls for the AR CAG repeat length was similar. There were no significant associations of CAG repeat length with prostate cancer risk when stratified by treatment arm (finasteride or placebo), or when combined. There was also no significant association between CAG repeat length and the risk of low or high grade prostate cancer. CONCLUSIONS: There is no association of AR CAG repeat length with prostate cancer risk. Knowledge of AR CAG repeat length provides no clinically useful information to predict prostate cancer risk.